Health Sector Updates: Breakthroughs and Challenges
The latest health news covers FDA's extended review of KalVista's drug, UroGen's new bladder cancer treatment approval, reinstatement of CDC employees, AstraZeneca's AI deal in China, scrutiny over vaccine adviser oustings, Sun Pharma's leadership change, Trump-era policy impacts, Thermo Fisher's asset sale, BioNTech's acquisition of CureVac, and air pollution's fetal impacts.
The U.S. Food and Drug Administration has extended its review period of KalVista Pharmaceuticals' drug for dealing with hereditary swelling disorders, citing an overwhelming workload. In contrast, the FDA approved a new bladder cancer treatment from UroGen Pharma, boosting the company's stock by over 50%.
The Centers for Disease Control and Prevention is reversing layoffs from the Trump administration, rehiring 450 employees. Meanwhile, AstraZeneca has entered a significant $5.3 billion agreement with China's CSPC Pharmaceutical Group to develop chronic disease therapies, a strategic move aimed at reinvigorating its operations in China.
Controversy arises with U.S. Health Secretary Robert F. Kennedy Jr. replacing vaccine advisors allegedly influenced by pharmaceutical funding. Further, Trump's Medicaid cuts may jeopardize rural healthcare services. In corporate news, Thermo Fisher plans to sell part of its diagnostics unit, while BioNTech acquires CureVac to enhance mRNA cancer treatment research.
(With inputs from agencies.)
- READ MORE ON:
- FDA
- KalVista
- UroGen
- CDC
- AstraZeneca
- vaccine
- Sun Pharma
- Trump
- Medicaid
- air pollution
ALSO READ
Moderna's New Vaccine Faces Comprehensive Placebo-Controlled Trial
Top CDC Vaccination Expert Resigns Amid COVID Vaccine Schedule Changes
CDC Expert Steps Down Amid Vaccine Schedule Controversy
CDC Shake-Up: Key Vaccine Expert Resigns Amidst Controversial Schedule Changes
Chaos Erupts Over Altered COVID-19 Vaccine Guidelines
Google News